Profound Medical

PROF

Market cap $192M

Profound Medical Corp. (PRN:CA) Q4 2025 Earnings Call Transcript

Profound Medical (PROF) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.

Profound Medical (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care Profound Medical marks major milestone as the hospital launches its state-of-the-art iMRI suite to expand access to advanced prostate care

TORONTO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has completed its previously announced private placement of common shares to Canadian investors (the “Offering”).

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) is pleased to announce that it has increased the size of its private placement previously announced on December 19, 2025 (the “Offering”) in order to accommodate participation by a long-term existing investor.

Financing included participation by healthcare-dedicated investors alongside existing shareholders Financing included participation by healthcare-dedicated investors alongside existing shareholders

TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 common shares at a purchase price of $7.00 per share in a registered direct offering and a planned subsequent private placement in Canada of up to 571,428 common shares at a purchase price of $7.00 per share for aggregate gross proceeds of up to $40 million. The registered direct offering was structured as a straightforward equity investment with no warrant coverage and was led by healthcare-dedicated investors alongside existing shareholders.

The consensus price target hints at an 82.4% upside potential for Profound Medical (PROF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.